These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27348272)

  • 1. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
    Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
    Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Hasselblom S; Hansson U; Olsson M; Torén L; Bergström A; Nilsson-Ehle H; Andersson PO
    Br J Haematol; 2010 May; 149(4):560-8. PubMed ID: 20201946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.
    Hong JY; Hong ME; Choi MK; Kim YS; Chang W; Maeng CH; Park S; Lee SJ; Do IG; Jo JS; Jung SH; Kim SJ; Ko YH; Kim WS
    Ann Oncol; 2014 Jan; 25(1):182-8. PubMed ID: 24356628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma.
    Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M
    Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB.
    Solomon LA; Batista CR; DeKoter RP
    Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
    Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
    Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity.
    Care MA; Cocco M; Laye JP; Barnes N; Huang Y; Wang M; Barrans S; Du M; Jack A; Westhead DR; Doody GM; Tooze RM
    Nucleic Acids Res; 2014 Jul; 42(12):7591-610. PubMed ID: 24875472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
    Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
    Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
    Wang J; Xu-Monette ZY; Jabbar KJ; Shen Q; Manyam GC; Tzankov A; Visco C; Wang J; Montes-Moreno S; Dybkær K; Tam W; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Wang S; Møller MB; Piris MA; Medeiros LJ; Li Y; Pham LV; Young KH
    Am J Pathol; 2017 Aug; 187(8):1700-1716. PubMed ID: 28627414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
    Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
    Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
    Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.
    Uddin S; Bu R; Ahmed M; Hussain AR; Ajarim D; Al-Dayel F; Bavi P; Al-kuraya KS
    Leuk Lymphoma; 2010 Jul; 51(7):1305-14. PubMed ID: 20443680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway.
    Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
    Arch Biochem Biophys; 2024 Aug; 758():110072. PubMed ID: 38914215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.
    Han J; Tang Y; Zhong M; Wu W
    Mol Med Rep; 2019 Dec; 20(6):5064-5074. PubMed ID: 31638226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.
    Lossos IS; Jones CD; Warnke R; Natkunam Y; Kaizer H; Zehnder JL; Tibshirani R; Levy R
    Blood; 2001 Aug; 98(4):945-51. PubMed ID: 11493437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.